STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Investor Presentation (January 2022)
30 slides from STRATA Skin Sciences's investor presentation, Jan 10, 2022
Slide 1: Driving Value to Dermatology Partners Matching Patients with Clinics
Investor Presentation December 2020 Investor Presentation January 2022 Driving Value to Dermatology Partners Matching Patients with Clinics
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,”
Slide 3: Addressing large markets for chronic skin diseases with laser-based treatments
3 Source: 1 Market Data Forecast Report 2021, Fortune Business Insights 2018, 2019 Addressing large markets for chronic skin diseases with differentiated laser-based treatments Recurring revenue model drives repeat and sustainable revenues Customer base of ~1K partner practices and growing Sales dri
Slide 4: Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions
Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions 4 CEOCFOVP MarketingVP of Professional RelationsDirector of Business Operations2 new Board Members (Chairman & Head of Audit Committee) New Leadership Commercial Focus and Execution Acquisitions DTC marketing analyticsDir
Slide 5: Executive Management Team: 100+ yrs. dermatology experience
Executive Management Team: 100+ yrs. dermatology experience Robert (Bob) J. Moccia, CEO Encore Dermatology, Precision Dermatology, Medicis Pharmaceuticals, Graceway Pharmaceuticals, Bioglan Pharmaceuticals, Stiefel Laboratories, Dermik Laboratories (RPR) Chris Lesovitz, CFO Encore Dermatology, Iroko
Slide 6: Strata Dermatology Markets Addressed
Strata Dermatology Markets Addressed Psoriasis Eczema (Atopic Derm.) Vitiligo Acne 6 Psoriasis Treatment Market* Size (2019 to 2027)2019 Global Market Value of $20.1B USD 1Projected Market Value of $40.6B USD by 2027 1CAGR of 9.2% 2020-2027 1 Eczema Treatment Market* Size (2020 to 2026)2020 Global M
Slide 7: Growing Demand for Drug-Free Treatment Options
Growing Demand for Drug-Free Treatment Options 7 Source: Dermatology Devices Report, Grand View Research 2021 Base year 2020, historic information 2016 to 2019, and forecast 2021 to 2028 USD Millions USD Millions $7.1B $34.1B $5.1B $993M Projected CAGR +21.2%2021-2028 Projected CAGR +19.9%2021-2028
Slide 8: XTRAC Treatments by Indication – United States
XTRAC® Treatments by Indication – United States 8 5% 80% 15% Opportunities exist for expanding use for other approved indicationsVitiligo Eczema (Atopic Dermatitis) #1use for XTRAC® lasers domestically Psoriasis treatments remain
Slide 9: Treatment Options Addressing Psoriasis Indication
Treatment Options Addressing Psoriasis Indication6 9 XTRAC NB-UVB* Topical Steroids Non-biologic Systemics Biologics Approximate Costs ($) Cost competitive 1K-3K 3K-9K 1K -7K 1K 32K-68K Clinical Impact Better clinical outcomes (PASI%75) 92% 71% 75% 48% 50-70% Speed of Onset (in weeks) Very fast rate
Slide 10: XTRAC is the Leader in Targeted 308nm Excimer Laser Therapy
Best-in-class Excimer TREATMENT XTRAC® is the Leader in Targeted 308nm Excimer Laser Therapy 10 Safe & Effective Treatment 150+ Peer-reviewed clinical studies Economical for patients and payors Win-Win for providers and their patients
Slide 11: Growing Installed Base Drives Recurring Revenue Model
Growing Installed Base Drives Recurring Revenue Model 11 01/01/19 Systems 12/31/19 1/01/20 12/31/20 Systems 12/31/21 01/01/21 Systems Net Installed Base Growth 2019-2021 27% growth in installed base over the last 3 years Actively redeploying under utilized devices Group and international placements
Slide 12: A True Partnership – Delivering a Complete Business Solution
A True Partnership – Delivering a Complete Business Solution 12 Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Assistance DTC Marketing
Slide 13: Partner Academic Institutions
Partner Academic Institutions 13
Slide 14: Key Priority: Driving Commercial Execution
Key Priority: Driving Commercial Execution 14 Sustain investment in DTC marketing Continue to focus and grow high-volume accounts Drive increased utilization across all indications Increase marketing to drive awareness among derms Historical trends show positive correlation between DTC investment an
Slide 15: Domestic Installed Base Growth Drivers
Domestic Installed Base Growth Drivers 832 1,962 251* XTRAC Partners Group Clinics As of 12/31/20 As of 12/31/19 1,962 clinics owned by 49 roll-up groups at 12/30/2020251 (13%) of which are XTRAC partners at 12/30/2020Signed strategic expansion agreements with major groupsIncreased from 251 at 12/30
Slide 16: Domestic Market: Installed Base – Sales and Service Engine
Domestic Market: Installed Base – Sales and Service Engine Overview890 Partner XTRAC® Clinics200+ Sold XTRAC4 Regions30 Sales Territories2 National Account Managers15 Field Service TechsIn-House Call Center to Qualify LeadsPredominant Provider of Excimer Laser Treatments 16 Territories color coded
Slide 17: International Market: Installed Base Strategic Growth Targets
International Market: Installed Base Strategic Growth TargetsCurrent Markets: China, Japan, Saudi Arabia, S. KoreaRecent approval in IsraelInsurance covered in most marketsUsage per device higher than domestic market1,300 OUS devices sold and in servicePlacement recurring revenue model agreements:Ex
Slide 18: Integration of the U.S. Pharos Dermatology Business of Ra Medical Systems
Integration of the U.S. Pharos Dermatology Business of Ra Medical Systems 18 250+ Pharos service contract holders contacted by XTRAC® representative to discuss options going forward74 service calls made by STRATA field service technicians since close13 Pharos users transitioned to XTRAC® in first 6
Slide 19: Recent Acquisition of Novel Acne Treatment
Recent Acquisition of Novel Acne Treatment 19
Slide 20: Theraclear Acquisition
Theraclear Acquisition 20 Substantially broadens STRATA’s opportunity with expansion potential into the estimated $5.5 billion acne care market Leverages STRATA’s innovative marketing platform, commercial team and worldwide distributor network to drive additional revenue growth Creates a robust pipe
Slide 21: Commercial Drivers in 2022
Commercial Drivers in 2022 21 Continue DTC advertising campaign with social media XTRAC® Awareness: Co-Op advertising to suitable patients (digital + print) Develop patient advocacy partnerships Broadened commercial strategy to expand use within partner practices Added emphasis on professional relat
Slide 22: Fourth Quarter and Full Year 2021 Financial Highlights
Fourth Quarter and Full Year 2021 Financial Highlights 22 Fourth Quarter and Full Year 2021 Financial HighlightsPreliminary, unaudited total revenue is expected to range from $8.8 million to $9.2 million, compared to $6.7 million in the fourth quarter of 2020Preliminary, unaudited total revenue for
Slide 23: Financial Metrics
Financial Metrics 23 * Total recurring revenue over total installed base** Company estimates not provided Unaudited quarterly results * See press release dated November 10, 2021 for definitions of non-GAAP measures 2018 Q1 '19 Q2 '19 Q3 '19 Q4 '19 2019 Q1 '20 Q2 '20 Q3 '20 Q4 '20 2020 Q1 '21 Q2'21 Q
Slide 24: STRATA Key Investment Takeaways
STRATA Key Investment Takeaways 24 Differentiated Treatment providing a Win-Win-Win for Patients + Clinics + Payers Addressing Large and Growing Markets +Positioned for Inorganic Growth Proven Business Model to Expand + Achieve Sustainable Results and Shareholder Returns
Slide 25: Thank You
Investor Presentation December 2020 Thank You
Slide 26: Appendix
Investor Presentation December 2020 Appendix
Slide 27: Board of Directors
Board of Directors William Humphries Chairman of the Board andGovernance & Compensation Committee CEO, Isosceles Pharmaceuticals, Inc. former President & Group Chairman Ortho Dermatologics, Merz Pharmaceuticals, , Stiefel Pharmaceuticals, , Allergan Pharmaceuticals Dr. Uri Geiger CEO Accelmed Inc. C
Slide 28: Sample Studies From 150+ Clinical Studies
Multicenter Psoriasis Study7 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or better after 10
Slide 29: XTRAC: Psoriasis
29 After 4 tx After 2 tx Baseline Clinical Protocol – 6.2 treatments to PASI 75 Beam of UVB light applied to the affected area PASI – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis XT
Slide 30: XTRAC: Vitiligo
XTRAC®: Vitiligo 30 Beam of UVB light applied to the affected area XTRAC®The solution for Vitiligo Results in re-pigmentation UVB light reduces the immune system’s attack on the melanocytes Simple, safe, effective + long-lastingExcimer laser Baseline After 18 tx After 29 tx
STRATA Skin Sciences — Investor Presentation (January 2022) on 6ix